Flerie AB (publ) (FLERIE.ST) Research

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.

Market snapshot

Symbol
FLERIE.ST
Price
$20.50
Day change
-1.91%
Market cap
$1.9B
P/E ratio
-2.80x
52-week range
20.4-41.7375
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 17 days

Peer companies

  • BioInvent International AB (publ) (BINV.ST)
  • Diamyd Medical AB (publ) (DMYD-B.ST)
  • Devyser Diagnostics AB (publ) (DVYSR.ST)
  • Egetis Therapeutics AB (publ) (EGTX.ST)
  • Hansa Biopharma AB (publ) (HNSA.ST)
  • Humana AB (publ) (HUM.ST)
  • Implantica AG (IMP-A-SDB.ST)
  • Orexo AB (publ) (ORX.ST)

Open Flerie AB (publ) (FLERIE.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.